Quick navigation menu :

  1. Go to the content
  2. Go to main section's menu
  3. Go to Search tool
  4. Go to Help menu
  5. Go to modules
  6. Go to the list of keyboard shortcuts

Help menu :

  1. Sanofi Worldwide |
  2. Our Websites |
  3. Global Business Websites |
  4. Contact Us |
  5. Sitemap |
  6. Help
  1. Font size

    Reduce Increase  

Metabolic Disorders

Contact Us

sanofi-aventis (Malaysia) Sdn. Bhd. (334110-P)

Unit TB-18-1, Level 18
Tower B, Plaza 33
No.1 Jalan Kemajuan, Seksyen 13
46200 Petaling Jaya

Tel : +603 7651 0800
Fax: +603 7651 0801/2

Content :

Metabolic Disorders

Diabetes mellitus (DM) is the most common metabolic condition affecting the world population. Malaysia is the country with the highest prevalence of DM in the South East Asia region .


The prevalence of the disease has doubled from 4% of the population in the 1980’s to 8% of the population in the early 2000’s. This increasing trend is showing no signs of abetting despite many interventional and aggressive preventive and treatment modalities that have been developed in the recent years.

DM has both short and long term complications like neuropathy (afflicting the nerves), retinopathy (affects the eyes), Angiopathies (diseases of the blood vessels) and more. It’s also the leading cause of kidney failure in Malaysia accounting for over 40% of the patients with end stage renal diseases that’s secondary to DM.

Patients with DM are unable to control their glucose levels within an optimum level. The regulation and control of the body’s glucose is a complex metabolic process. It’s governed by many hormones, the primary hormone is the Insulin hormone. Insulin is produced from the pancreas. The imbalance in sugar (or glucose) controls comes with either a total absence or inadequate production of insulin and the insulin that’s being produced is not efficiently utilized by the body.

The disease can be classified as either Type 1 DM or Type 2 DM. Type 1 disease is usually diagnosed in the much younger age group, children and teenagers. The primary problem lies in there being absence of Insulin hormone secretion from the pancreas. Type 1 account for anything between 5-10% of the disease population. The Type 2 DM, which is the more common form of the disease accounts for 90-95% of those afflicted with DM. In this form, there is a dual problem of a progressively reducing production of Insulin from the body coupled with the desensitizing (increased insulin resistance) of the tissues to the insulin that being produced. 
Treatment of Diabetes Mellitus is a trifocal approach. There are treatments aimed at increasing the insulin secretion from the pancreas (endogenous insulin), to increase the sensitivity of the tissues to the insulin that’s being secreted and to provide an external source of insulin (exogenous insulin). 

In Type 1 DM the treatment is solely aimed at providing an external source of insulin. In Typ2 DM treatment usually starts with Oral Anti Diabetic medications and then to start on Insulin. The patients are then either on oral medication or insulin or a combination of both.

Sanofi aventis has some leading drugs in equipping the physicians with the fight against Diabetes Mellitus.

Updated August 28, 2009

Module :